STADA Arzneimittel AG (STDAF.PK,STDAY.PK) said in the current first quarter of 2012, it founded a subsidiary based in Sydney, Australia, under the name STADA Pharmaceuticals Australia Pty Ltd, which is expected to begin its business activities in the third quarter of 2012.
The company stated that by finding the new subsidiary, it would like to benefit from the growth opportunities available in the Australian generics market as well as further expand its presence in the growth region Asia/Pacific.
According to STADA Arzneimittel, in view of expiring patents from the year 2012 to 2014 with sales at current ex-factory prices in the amount of around A$ 2.1 billion, high growth is expected in the Australian generics market. Further growth opportunities are also emerging as a result of the current relatively low generics penetration of less than 40% in Australia, the company added.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.